Literature DB >> 7779407

Immunolocalisation of vascular endothelial growth factor in human endometrium.

X F Li1, J Gregory, A Ahmed.   

Abstract

Angiogenesis is an essential component of endometrial regeneration after menses in preparation for implantation. Vascular endothelial growth factor (VEGF) is a secreted angiogenic peptide with mitogenic activity specific for endothelial and trophoblast cells. VEGF-immunoreactivity was detected in glandular epithelium throughout the menstrual cycle by immunohistochemistry, but, showed cyclic variation in the stroma and the blood vessels. During the early proliferative phase, strong staining was seen in the glandular epithelial cells while staining in the stroma was confined to a subpopulation of stromal cells and endometrial blood vessels appeared negative. In contrast, very intense staining of the endometrial stromal cells was seen in the mid proliferative endometrium possibly due to increased synthesis of VEGF by oestrogen. In the late proliferative endometrium, staining was seen in the endothelial cells and the perivascular stromal cells around the endometrial blood vessels. The greatest degree of immunostaining of stromal cells was observed in the mid to late proliferative endometrium. Throughout the secretory phase no staining was seen around the endometrial blood vessels and staining of endometrial stromal cells was confined to early secretory endometrium. In the late secretory endometrium only the glands were positive to VEGF antibody. The observed increase in the immunostaining of stroma suggests increased production of VEGF from early to mid and late proliferative endometrium which parallels the increase in the oestradiol levels in the proliferative phase of the menstrual cycle. It is proposed that VEGF may serve as a paracrine mediator of the effects of ovarian steroids on endometrial vascular development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7779407     DOI: 10.3109/08977199409011000

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  10 in total

1.  Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site.

Authors:  A Ahmed; X F Li; M Shams; J Gregory; T Rollason; N M Barnes; J R Newton
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

2.  Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids.

Authors:  J McLaren; A Prentice; D S Charnock-Jones; S A Millican; K H Müller; A M Sharkey; S K Smith
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Down-regulation of angiopoietin-1 expression in menorrhagia.

Authors:  Peter Hewett; Sarbjit Nijjar; Munjiba Shams; Susan Morgan; Janesh Gupta; Asif Ahmed
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.

Authors:  T Fujisawa; J Watanabe; Y Kamata; M Hamano; H Hata; H Kuramoto
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

Review 5.  Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis.

Authors:  K P Claffey; G S Robinson
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

6.  Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.

Authors:  J Fujimoto; H Sakaguchi; R Hirose; S Ichigo; T Tamaya
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers.

Authors:  J Fujimoto; H Sakaguchi; I Aoki; S Khatun; T Tamaya
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

8.  Gene expression analysis of VEGF and its receptors and assessment of its serum level in unexplained recurrent spontaneous abortion.

Authors:  Elham Amirchaghmaghi; Abbas Rezaei; Ashraf Moini; Mohammad Ali Roghaei; Maryam Hafezi; Reza Aflatoonian
Journal:  Cell J       Date:  2015-01-13       Impact factor: 2.479

9.  The anti-angiogenic isoforms of VEGF in health and disease.

Authors:  Yan Qiu; Coralie Hoareau-Aveilla; Sebastian Oltean; Steven J Harper; David O Bates
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

Review 10.  Trophoblast 'pseudo-tumorigenesis': significance and contributory factors.

Authors:  Rama Soundararajan; A Jagannadha Rao
Journal:  Reprod Biol Endocrinol       Date:  2004-03-25       Impact factor: 5.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.